17: Infectious Diseases and Vaccines Flashcards

1
Q

Which type of response controls mucosal or barrier infections?

A

T(H) 2 type
Especially anti-helminth immunity

Activation of ILC2s, T(H)2 specific cytokines (i.e. IL-4 and IL-13), and IgE capable of recognizing surface epitopes of the pathogen.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Extracellular response:

A
Controlled by a combination of innate and adaptive effector mechanisms:
- Phagocytosis and pAPC activation 
  (via PRR binding and cytokines)
- Complement activation
- Antibody binding

T(H)2 and T(H)17

Against bacteria, helminths and fungi.

B cells
mIgA, IgM, IgG

Phagocytic cells

Antimicrobial compounds.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Intracellular infections

A

Most difficult to detect

Membrane-bound or cytosolic:
Different immune response mediators

In vesicles:
Most effective eradicated via macrophages activated by the cytokines secreted by T(H)1 cells.

Cytosol:
Requires host cell lysis by CTLs (generated with DC-licencing help from T(H)1 cells), cytotoxic T(H)1 cells, or NK cells.

Example:
T(H)1 cells can recruit and activate macrophages, which surround dead and dying infected cells that harbor the bacteria, walling off the bacteria from spreading further and, in some cases, clearing the debris.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Intracellular infections

A

Most difficult to detect

Membrane-bound or cytosolic:
Different immune response mediators

In vesicles:
Most effective eradicated via macrophages activated by the cytokines secreted by T(H)1 cells.

Cytosol:
Requires host cell lysis by CTLs (generated with DC-licencing help from T(H)1 cells), cytotoxic T(H)1 cells, or NK cells.

Example:
T(H)1 cells can recruit and activate macrophages, which surround dead and dying infected cells that harbor the bacteria, walling off the bacteria from spreading further and, in some cases, clearing the debris.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Antiviral innate response

A

Encounter with viral PAMPs
=>
Secretion of type 1 interferons, inflammasome and NK-cell activation, IL-12 production

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Humoral response: viruses

A

Antibody (especially IgA)
- Blocks binding of virus to cells

IgG, IgM (and IgA)
- Block fusion of viral envelope with 
  host cell's plasma memb. 
- Enhance phagocytosis 
  (opsonization)

IgM
- Agglutinate viral particles

Complement activated by IgM or IgG
- Mediates opsonization by C3b 
  and lysis of enveloped viral 
  particles (and infected cells) by 
  membrane-attack 
  complex
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Cell-mediated response: viruses

A

IFNγ secreted by T(H) or T(C) cells
- Direct antiviral activity

Cytotoxic T-lymphocytes
- Kill virus-infected self-cells

NK + macrophages
- Kill virus-infected cells by Ab-dependent cell-mediated cytotoxicity (ADCC)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Evasion strategies of viruses

A

Expression of immune-blocking or -inhibiting compounds

Suppression of MHC class I expression

Regularly changing surface Ag’s (Ag drift)

Delivery of instructions that misdirect the host immune response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Immunotoxins

A

Induces local inflammatory response by extracellular bacteria.

Endotoxins:
Integral components of the bacterial cell wall, i.e., lipopolysaccharide (LPS)

Exotoxins:
Secreted toxic proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Antibody-mediated mechanisms for combating infection by extracellular bacteria (Figure 17-5, p. 652)

A
  1. Antibody neutralization of
    bacterial exo- or endotoxins
  2. Complement-mediated lysis
  3. Opsonization (by C3b) and
    phagocytosis
  4. Anaphylatoxins (complement
    peptides: C3a, C5a) mediate
    mast cell degranulation.
  5. Recruitment of neutrophils and
    macrophages.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Bacterial evasion mechanisms

A

Attachment to host cells

Block IgA

Inhibit complement

Change antigenic structure

Inhibit phagocytosis or phagosome lysosome fusion => avoid intracellular degradation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Parasite infections

A

Includes:

  • Unicellular protozoans
  • Metazoans (helminths or worms)

Immune response depends on:

  • Mode of immune detection
  • Parasitic stage
  • Location

Typically generate weak immune responses

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Helminths

A

Enter hosts intestinal tracts
Exclusively extracellular

Weak immune response
- T(H)2-type responses, incl. ILC2s, IL-4 and IgE production

Evasion:

  • Decrease external Ag expression
  • Wrap themselves in host proteins to limit immunity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Fungal infections

A
Innate immunity:
- PRR recognition of common surface 
  structures
- Neutrophils
- Complement

Adaptive immunity may be acquired

  • Ab’s
  • T(H)1, (T(H)17)

Evasion:
- Capsules => prevent PRR binding
- Fungi-induced expulsion from
macrophages.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Emerging and reemerging infectious diseases

A

Reasons:

  • Crowding in cities
  • International travel (i.e., West Nile virus)
  • Improper antibiotic use (resistant strains)
  • Laxity in vaccination program adherence
  • Combinations of diseases (i.e., HIV and tuberculosis)
  • Zoonotic pathogens (Ebola primary host is fruit bat)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Passive immunity

A

Temporary
Does not engage the host’s immune response or generate memory
Can be acquired naturally or delivered artificially
Protect from subsequent infectious disease, recent venom exposures, and in those who lack humoral responses.

16
Q

Active immunity

A

Natural infection or artificial exposure

Goal: induce memory response that will be protective in the future.

17
Q

Live Attenuated vaccines

A

Produce most robust response.
Developed by genetic engineering and culturing methods. Remove genes that are necessary for virulence.

Advantages:

  • Prolonged immune system exposure because of growth capacity
  • Often only require a single immunization => advantage in developing countries

Disadvantages:

  • Can sometimes mutate and revert to a more virulent form in the host
  • Can get similar complications as with natural disease
18
Q

Inactivated (“killed”) vaccines

A

Inactivation by heat or chemicals. Chemicals are favorable because heat can denature proteins and epitopes on the virus surface.

Often require booster doses.
Humoral/Ab mediated response as they don’t replicate in the host.

Risks:

  • incomplete inactivation of virus can lead to disease.
  • infection of the persons producing the vaccine
19
Q

Subunit vaccines

A

Uses only specific, purified macromolecules derived from the pathogen; subunit approach.

Applications:

  • Inactivated pathogen exotoxins (toxoids)
  • Isolated capsular polysaccharides or surface glycoproteins
  • Purified key recombinant protein antigens

Can’t activate T(H) cells

20
Q

Recombinant vector vaccines

A

Prolong immunogen delivery and encourage cell-mediated responses.
Cannot revert to pathogenic form.

Safe attenuated viruses/bacteria serves as live carriers (vectors).

21
Q

DNA vaccines

A

Plasmid DNA encoding antigenic proteins.

Important to deliver pDNA directly or indirectly into local APCs, as myocytes express low levels of MHC class I and no costimulatory molecules.

Booster shot(s) or the addition of supplementary DNA sequences into the vector may enhance the immune response.

Advantages:

  • No denaturation or modification of protein as it is expressed in the host.
  • Ag similar to that of the pathogen => induces humoral and cell-mediated immunity.
  • No refrigeration; can be stored longer
  • Same plasmid can be used to insert DNA encoding different proteins => simultaneous manufacture => save time and money
  • Initially: safety concerns
  • Variable delivery doses
  • Transient gene expression
  • Poor immunogenicity